• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Prostate-Specific Antigen screening of elderly men varies significantly in primary care

bys25qthea
October 16, 2013
in Chronic Disease, Oncology, Urology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1. Primary care physicians accounted for 27% of the variance in whether an elderly man (>75 years old) received a PSA screen. 

2. Variance in PSA screening among elderly men attributable to PCPs (0.27) is higher than mammography (0.10) and colorectal cancer (0.09) screening. 

Evidence Rating Level: 3 (Average) 

Study Rundown: Prostate-specific antigen (PSA) screening has ignited significant controversy in recent years. For men 75 years or older, however, the medical community is generally in agreement: no PSA screening is recommended. Despite this, elderly men are still commonly screened in the community. This study identified the role of primary care physicians (PCP) in determining whether an older man received a PSA screen. The authors found a 10-fold difference in screening rates between the highest and lowest deciles of PCPs. In a model that evaluated PCP’s ordering of PSA testing, the intra-class correlation coefficient (ICC), which represents the percentage of variance attributable to the patient’s PCP, was 0.27. The ICC among PCPs for PSA screening stands in contrast to other studies that have demonstrated a ICC of 0.10 for mammography and 0.09 for colorectal cancer screening. This study is notable for a large sample size, but is limited due to analysis of data from a single year in only one state. Nonetheless, these findings suggest confusion among PCPs about the value of PSA screening in elderly men. Future research is needed to better characterize this high variability.

Click to read the study, published today as a Research Letter in JAMA

Relevant Reading: Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians

RELATED REPORTS

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

In-Depth [cross-sectional study]: This cross-sectional study identified 1,963 PCPs with patient panels that included 61,351 men aged 75 or older. The authors used Medicare Part A and B data for Texas in 2010 to conduct a multi-level, multi-variable logistic regression analysis and controlled for patient characteristics such as race/ethnicity, comorbidities, and Medicaid eligibility among others. Overall, 41% of men received PSA screening, of which 28.8% was ordered by their PCP. Screenings with PSA significantly decreased with age. The intra-class correlation coefficient (ICC) was 0.27, which means that 27% of the variance in PSA screening was attributed to the patient’s PCP. Patient characteristics such as age, comorbidities, or race/ethnicity accounted for only 3.7% of the observed variance.

By Jonathan Lichkus and Rif Rahman

More from this author: Younger women more likely than men to present with acute coronary syndrome without chest pain

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: prostate cancerPSA
Previous Post

Regular bedtime helps behavior in children

Next Post

In diabetics, coronary bypass surgery and percutaneous coronary intervention similar

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 13, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

March 28, 2022
#VisualAbstract: Abiraterone acetate improves survival in high-risk non-metastatic prostate cancer compared to control
StudyGraphics

#VisualAbstract: Abiraterone acetate improves survival in high-risk non-metastatic prostate cancer compared to control

February 16, 2022
Next Post
Remote ischemic preconditioning reduced myocardial injury in CABG patients

In diabetics, coronary bypass surgery and percutaneous coronary intervention similar

VATS lobectomy may be preferred in COPD with non-small-cell lung cancer

VATS lobectomy may be preferred in COPD with non-small-cell lung cancer

Sleeve gastrectomy surgery linked to more weight loss than lap-band

Deliberate practice in virtual reality simulator improves surgical resident performance

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.